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 Introduction 
 Nonalcoholic fatty liver disease (NAFLD)  is a clinico-
pathological condition of emerging importance, and is 
now recognized as the most common cause of abnormal 
liver tests. NAFLD is associated with obesity, type 2 dia-
betes, dyslipidemia and hypertension. These conditions 
have insulin resistance as the common factor and cluster 
to form the metabolic syndrome. Most patients with 
NAFLD have increased liver fat content alone (simple ste-
atosis), but others develop increasing hepatic inflamma-
tion known as nonalcoholic steatohepatitis (NASH). A 
significant number of NASH patients – but not all – de-
velop progressive fibrosis, ultimately leading to cirrhosis, 
hepatocellular carcinoma and end-stage liver disease  [1] .
 Current Model of Disease Progression in NAFLD 
 A wealth of studies in animal models and humans 
with this disorder have increased our understanding of 
the pathogenesis and progression of NAFLD; however, 
the underlying mechanisms that influence the progres-
sion of steatosis to steatohepatitis are still largely un-
known. We do know even less about the factors that cause 
development and progression of fibrosis in NAFLD.
 The ‘two-hit model’ has been suggested to describe the 
development and progression of ‘simple’ fatty liver and 
NASH, respectively  [2] . The first hit causes hepatic ste-
atosis, i.e. an imbalance between hepatocellular lipid up-
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 Abstract 
 Nonalcoholic fatty liver disease (NAFLD) starts with hepatic 
steatosis, which can progress with inflammation to nonalco-
holic steatohepatitis, and a subset of patients develop pro-
gressive fibrosis and ultimately cirrhosis. In the majority of 
cases, NAFLD is associated with (components of) the meta-
bolic syndrome. Obesity, diabetes and hepatic steatosis are 
also independent risk factors for hepatic fibrosis in different 
chronic liver diseases. However, the question is whether it is 
actually nonalcoholic steatohepatitis and not ‘simple’ ste-
atosis that promotes fibrosis progression based on hepato-
cellular injury. In this review, the concept will be put forward 
that (1) hepatic steatosis per se is profibrogenic, and (2) that 
in NAFLD development and progression of hepatic fibrosis is 
not simply determined by (the degree of) hepatic inflamma-
tion. In addition to the liver, this view is expanded to other 
organs affected by the metabolic syndrome, which affects 
hepatic injury and fibrosis also via extrahepatic pathophysi-
ological alterations. In conclusion, fatty liver and the meta-
bolic syndrome, respectively, have to be recognized as sig-
nificant lubricants of hepatic fibrosis, and simple hepatic ste-
atosis cannot be considered as benign. 
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take on the one hand and lipid combustion and secretion 
on the other. Subsequently, a second hit is required to 
 induce NASH, i.e. a situation where proinflammatory 
mechanisms overcome anti-inflammatory mechanisms 
( fig. 1 ). Several excellent reviews have summarized our 
current knowledge of mechanisms, which tip the balance 
towards steatosis and inflammation, respectively  [1, 3] . 
For example, lipid peroxidation has been identified to in-
duce increased DNA oxidative damage and cell death, 
and herewith, hepatic inflammation. However, hepatic 
(necro)inflammation does not appear to be sufficient for 
progression to severe fibrosis since progression from 
NASH to cirrhosis develops only in a fraction of patients. 
Actually, several lines of evidence indicate that hepatic 
fibrosis is not simply the obligatory consequence of he-
patic inflammation, but a ‘third hit’ (or ‘third hits’) is re-
quired to initiate and perpetuate fibrogenesis. 
 Direct Effect of Hepatic Steatosis on Hepatic Fibrosis 
 Hepatic fibrosis is characterized by an increased depo-
sition of extracellular matrix proteins as a result of in-
creased fibrogenesis and decreased fibrolysis. Activated 
hepatic stellate cells (HSCs) are the effector cells of he-
patic fibrosis. After hepatic injury, HSCs undergo an ac-
tivation process and transform to an activated myofibro-
blast-like phenotype. They are responsible for the exces-
sive hepatic extracellular matrix deposition and their 
activity is recognized as a central event in the develop-
ment of hepatic fibrosis  [4, 5] . Also in NAFLD, HSC acti-
vation is the central pathophysiological mechanism un-
derlying hepatic fibrosis, which has to be kept in mind 
when searching for factors causing or enhancing the 
‘third hit’.
 To gain insight into the molecular mechanisms link-
ing hepatic steatosis to fibrogenesis, we established an in 
vitro  model to study the effect of hepatic steatosis on 
HSCs  [6] . In this model, a dose-dependent lipid accumu-
lation in primary human hepatocytes was induced by in-
cubation with free fatty acids. Subsequently, HSCs were 
stimulated with conditioned medium collected from lip-
id-loaded and control hepatocytes, respectively. Applying 
this system, we found that steatotic hepatocytes release 
soluble factors, which enhance proinflammatory and 
profibrogenic gene expression in HSCs, and furthermore 
induce their activation, proliferation and resistance to 
apoptosis  [6] . These in vitro data strongly indicate that 
pure fatty liver has the potential to promote liver fibrosis 
independent of inflammatory cells or hepatic inflamma-
tion. There is also increasing in vivo evidence that simple 
steatosis can ‘bypass’ the second hit, i.e. directly affecting 
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 Fig. 1. The ‘three-hit model’ for the progression of NAFLD. Obe-
sity and the metabolic syndrome reached a pandemic dimension, 
and most of these individuals have fatty liver also in the absence 
of significant chronic alcohol consumption (nonalcoholic fatty 
liver). In a significant number of cases, steatosis progresses to 
(nonalcoholic) steatohepatitis, and a subset of patients further 
 develop fibrosis, which may lead to cirrhosis. The ‘hit model’ is 
based on the hypothesis that there is an imbalance between hepa-
tocellular lipid uptake on the one hand and lipid combustion and 
secretion on the other, which constitutes the ‘first hit’. The ‘second 
hit’ is caused by an imbalance of pro- and anti-inflammatory fac-
tors, which leads to hepatic inflammation. Finally, a ‘third hit’, i.e. 
an imbalance of pro- and antifibrotic factors, leads to progressive 
hepatic fibrosis, which may ultimately lead to cirrhosis. 
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hepatic fibrosis. Thus, it has been shown by Deems at al. 
[7] that a high-fat diet exacerbates hepatic fibrosis in the 
bile duct-ligation model in mice. 
 Further, we demonstrated significantly elevated he-
patic expression of RANTES and MCP-1 to be an early 
event in NAFLD progression, which occurs in hepatic 
steatosis without hepatic inflammation  [8] . Both che-
mokines have been shown to play a critical role in he-
patic fibrosis, and part of the profibrogenic effect is also 
mediated via direct effects on HSCs and herewith inde-
pendent of hepatic inflammation  [10] . Moreover, Taran-
tino et al. [11] found enhanced serum concentrations of 
transforming growth factor (TGF)-  1 in NAFLD pa-
tients, which were similar in patients with steatosis and 
NASH. TGF-  1 is one of the most potent profibrogenic 
cytokines; therefore, this study further suggests that he-
patic steatosis cannot be considered as benign, but as 
harboring direct profibrogenic potential. Furthermore, 
histological examination of NAFLD patients revealed 
that severe steatosis and panacinar steatosis were more 
often associated with advanced fibrosis and herewith 
indicates that the location and degree of lipid accumula-
tion affect the pathophysiological potential of hepatic 
steatosis  [12] .
 Insulin Resistance and Fibrosis 
 In the majority of cases, NAFLD is associated with 
(components of) the metabolic syndrome. In fact, NAFLD 
itself is considered as a component of the metabolic syn-
drome. Therefore, it has to be considered that fatty liver 
is flanked by diabetes and/or high insulin levels in most 
cases, and that this is critical for hepatic fibrosis. Thus, it 
has been shown that high glucose concentrations induce 
proliferation and collagen production by HSCs  [13] . Fur-
ther, high glucose and hyperinsulinemia stimulate ex-
pression of further fibrogenic factors in HSC in vitro and 
in vivo in experimental models of obesity and type II di-
abetes  [14] . Moreover, a recent study by Ota et al. [15] 
compared the effect of a high-fat diet on two strains of 
rats. OLETF rats are prone to obesity, insulin resistance, 
hyperinsulinemia and diabetes, while LETO rats are lean 
and insulin-sensitive. Interestingly, in OLETF rats, a 
high-fat diet led to increased hepatic triglyceride accu-
mulation and inflammation as well as HSC activation 
and fibrosis, while the hepatic response was significantly 
milder in LETO rats. In line with this study, Lo et al. [16] 
described that diabetes is a progression factor for hepatic 
fibrosis in a high-fat diet model of NASH, and Nan et al. 
 [17]  showed that treatment with an antidiabetic drug 
ameliorates fibrosis in an experimental murine NASH 
model. Accordingly, a long-term follow-up study of 
NAFLD patients revealed that progression of liver fibro-
sis is associated with more pronounced insulin resistance 
and significant weight gain  [18] . 
 Together, these findings indicate that insulin resis-
tance and/or diabetes may accelerate the entire patholog-
ic spectrum of NAFLD. Intriguingly, fibrosis is affected 
directly and (at least in part) independently of the effect 
on hepatic inflammation. Of note, the profibrotic action 
does not even necessarily require hepatic lipid accumula-
tion. Thus, the metabolic syndrome is independently as-
sociated with more severe fibrosis, but not with the sever-
ity of steatosis, both in chronic viral hepatitis and NASH 
 [19] . Consequently, a recent study of livers of diabetics 
found activation of HSCs and sinusoidal fibrosis without 
histologically detectable NASH and irrespective of the 
degree of steatosis  [20] . Similarly, Abrams et al. [21] 
showed that a significant subset of morbidly obese indi-
viduals had portal fibrosis in the absence of NASH, which 
is associated with glycemic dysregulation. 
 Although the pathogenic mechanisms implicated in 
the association of diabetes and fibrosis are presently un-
known, high extracellular and intracellular glucose envi-
ronment may activate several pathways related to the pro-
duction of cytokines, growth factors and reactive oxida-
tive species, which can mediate tissue damage and 
fibrosis in diabetes. In 2001, Paradis et al. [14] suggested 
that hyperglycemia and insulin are key factors in the pro-
gression of fibrosis in patients with NASH through the 
upregulation of connective tissue growth factor, a key 
factor of hepatic fibrosis  [22] . Of note, there are intriguing 
similarities between the association of diabetes and fibro-
sis in the liver and in other organs. Thus, experimental 
models have indicated that hyperglycemia influences the 
severity of pulmonary fibrosis  [23] . Additionally, several 
clinical studies have revealed an association between dia-
betes and pulmonary fibrosis  [24, 25] . Moreover, experi-
mental diabetes mellitus leads to upregulation of profi-
brotic genes and fibrosis in the myocardium  [26, 27] . In 
the heart, connective tissue growth factor also appears as 
a mediator of adverse effects of high glucose and fatty ac-
ids in cardiomyocytes  [28] . Interestingly, connective tis-
sue growth factor has also been implicated in the epithe-
lial-to-mesenchymal transition of renal tubular epithelial 
cells, which contributes to the renal fibrosis associated 
with diabetic nephropathy  [29] .
 Together, these findings clearly indicate that diabetes 
and insulin resistance are significant promoters of fibro-
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sis in general, and with regard to NAFLD, they further 
show that the metabolic syndrome can bypass the first 
and second hit, i.e. can directly affect hepatic fibrosis.
 Extrahepatic Manifestations of the Metabolic 
Syndrome Promote Hepatic Fibrosis 
 Diabetes and insulin resistance highlight how impor-
tant it is to consider that NAFLD occurs in the context of 
a systemic disease, and thus differs from most other liver 
diseases. Moreover, in NAFLD several other organs and 
biological functions are affected in addition to the liver, 
and these alterations directly or indirectly promote in-
flammation and fibrosis in fatty liver.
 One example is visceral adipose tissue, in which ex-
pression and secretion of adipocytokines is quantitative-
ly and qualitatively altered in obese patients  [30] . On the 
one hand, expression of adiponectin, which is known to 
be hepatoprotective and antifibrotic, is significantly re-
duced. On the other hand, obese patients frequently have 
increased levels of leptin, another adipokine mainly re-
leased by adipocytes, and associated leptin resistance  [31] . 
Leptin is profibrogenic and liver fibrosis is decreased in 
leptin- or leptin receptor-deficient mice  [31, 32] . A recent 
study found that leptin directly promotes the myofibro-
blastic phenotype in HSCs by activating the hedgehog 
pathway  [33] .
 Another example how the complexity of the metabol-
ic syndrome or pathophysiological alterations associated 
with the metabolic syndrome may affect the progression 
of NAFLD is obstructive sleep apnea that causes chronic 
intermittent hypoxia during sleep. Obstructive sleep ap-
nea is frequent in obese individuals, and it has been 
shown that chronic intermittent hypoxia induces oxida-
tive stress in hepatocytes and predisposes to liver injury 
 [34] . Similarly, chronic intermittent hypoxia promotes 
the progression of NASH in animal models  [35, 36] . After 
exposure to chronic intermittent hypoxia, mice with diet-
induced hepatic steatosis developed lobular inflamma-
tion and fibrosis in the liver, which were not evident in 
control mice  [35] . Moreover, severe obstructive sleep ap-
nea has been identified as a risk factor for elevated liver 
enzymes and steatohepatitis independent of body weight 
in patients  [37] . Hypoxia leads to the activation of hypox-
ia-inducible factor 1 and 2. These oxygen-sensitive tran-
scription factors are important regulators of hepatic lipid 
metabolism and are known to play a critical role in he-
patic inflammation and fibrosis  [38] . Interestingly, a re-
cent study revealed that hypoxia also underlies the devel-
opment of the inflammatory response in adipocytes  [39] , 
which significantly contributes to systemic as well as he-
patic inflammation in the metabolic syndrome  [40] . This 
further indicates the complexity of the interaction of he-
patic and extrahepatic pathophysiological mechanisms, 
which promote the progression in NAFLD.
 Intestinal Effects of the Metabolic Syndrome 
Promote Hepatic Fibrosis 
 Obesity leads to quantitative and qualitative changes 
of the intestinal flora and an impaired intestinal barrier, 
which together lead to increased translocation of bacteria 
and bacterial compounds  [41, 42] known to be proin-
flammatory and profibrogenic ( fig. 2 ). Thus, in dietary 
NASH as well as other models of chronic liver injury, re-
duction of the number of intestinal bacteria by antibiotics 
ameliorates hepatic fibrosis  [43, 44] . In addition to the 
quantity, obesity and high-fat diets lead to changes in the 
composition of the intestinal flora in a deleterious way 
 [45–49] . Thus, high-fat diets promote the growth of en-
dotoxin-producing bacteria and bacteria with an in-
creased capacity for uptake of carbohydrates typical of a 
‘Western diet’  [45–47] . 
 In NAFLD, intestinal permeability is impaired by a 
loss of the integrity of epithelial tight junctions  [42] . Re-
cently, we have shown that experimental colitis leads to 
an increased expression of intestinal defensins which ap-
parently fosters the intestinal barrier  [50] . It is notewor-
thy, however, that this protective defensin expression was 
almost completely abrogated in mice fed a high-fat diet, 
and also portal endotoxin levels were significantly higher 
in these mice compared to animals with colitis but fed 
with normal chow  [50] . Further studies have to show 
whether this inhibitory effect of a high-fat diet on the in-
testinal barrier is also operative under less pronounced 
subchronic intestinal inflammation as observed in 
NAFLD patients.
 Furthermore and surprisingly, we recently revealed in 
experimental murine models that application of a high-
fat diet leads to a markedly increased hepatic expression 
of the endotoxin receptor Toll-like receptor 4 (TLR4), 
which is known to play a crucial role in hepatic fibrosis 
 [50, 51] . Under normal conditions, TLR-signaling path-
ways are inactivated although the liver is constantly ex-
posed to gut-derived bacterial products. Under patholog-
ical conditions, however, signaling via TLRs promotes 
antimicrobial responses and hepatic injury  [52] , and the 
crucial role of TLR4-signaling in hepatic fibrosis has re-
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but development and progression of hepatic fibrosis are 
subsequently determined by the degree of steatohepatitis. 
In contrast, fatty liver directly affects hepatic fibrosis in 
NAFLD as well as in chronic liver disease in general. 
Considering their epidemiological dimensions, it is im-
portant to further unravel the underlying mechanisms of 
how the metabolic syndrome and fatty liver, respectively, 
lubricate hepatic fibrogenesis. This knowledge could be 
the basis for novel prognostic markers and therapeutic 
targets of liver fibrosis in NAFLD and chronic liver dis-
ease in general.
 Disclosure Statement 
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cently been highlighted  [53] . Moreover, it has been shown 
that free fatty acids can activate TLR4 as pattern recogni-
tion receptors by mimicking pathogens  [54] . It is note-
worthy that free fatty acids are frequently elevated in 
obese patients and patients with NAFLD.
 Conclusion 
 The ‘hit model’ is a valuable framework for under-
standing the molecular mechanisms of disease progres-
sion in NAFLD. However, like every model it simplifies 
and depicts only part of the complexity of the pathophys-
iological mechanisms promoting progression of hepatic 
steatosis to inflammation and fibrosis. Thus, one has to 
consider that in addition to the liver, the metabolic syn-
drome pathophysiologically affects several other organs. 
Furthermore and importantly, there is clear evidence that 
steatosis is not only the basis for hepatic inflammation, 
CD14
TLR4
CD14
TLR4
CD14
TLR4
Inflammation Fibrosis
 Fig. 2. The metabolic syndrome affects the gut-liver interaction. 
Schematic depiction of the pathological alterations in intestine 
and endotoxin-induced signal transduction, respectively, by 
which the metabolic syndrome promotes hepatic inflammation 
and fibrosis. Obesity leads to quantitative and qualitative changes 
of the intestinal flora, i.e. higher number as well as a higher per-
centage of endotoxin-producing bacteria. Moreover, the intesti-
nal barrier is paired, which leads to increased translocation of 
bacteria and bacterial compounds. Hepatic steatosis and inflam-
mation induce expression of the endotoxin receptor Toll-like re-
ceptor 4 (TLR4), which (together with CD14) plays a crucial role 
in the development and progression of hepatic inflammation and 
fibrosis. With the progression of hepatocellular injury the intes-
tinal barrier is further impaired, leading to a vicious circle. 
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